Atara Biotherapeutics (ATRA) Common Equity (2013 - 2026)
Atara Biotherapeutics' (ATRA) quarterly Common Equity came in at -$37.3 million in Q1 2026, up 32.25% YoY from -$28.2 million in Q1 2025, and up 3.09% on a QoQ basis from -$38.5 million in Q4 2025.
Atara Biotherapeutics (ATRA) Common Equity (2013 - 2026) Analysis & Trends
Atara Biotherapeutics (ATRA) has 14 years of Common Equity data on file, last reported at -$37.3 million in Q1 2026.
- Quarterly Common Equity rose 32.25% year-over-year to -$37.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$37.3 million (up 32.25% YoY) and the FY2025 annual result came in at -$38.5 million, up 60.42% from the prior year.
- Common Equity improved to -$37.3 million in Q1 2026, from -$38.5 million in the prior quarter.
- In the past five years, Common Equity ranged from a high of $257.5 million in Q2 2022 to a low of -$110.9 million in Q2 2024.
- A 5-year average of $18.6 million and a median of -$36.6 million in 2025 frame the typical range for Common Equity.
- Annual changes were most pronounced in 2024 — Common Equity sank 1587.36% — and 2025, when it surged 68.39%.
- Tracing ATRA's Common Equity over 5 years: stood at $126.6 million in 2022, then fell by 21.64% to $99.2 million in 2023, then plunged by 198.04% to -$97.3 million in 2024, then surged by 60.42% to -$38.5 million in 2025, then grew by 3.09% to -$37.3 million in 2026.
- The last three Common Equity figures came in at -$37.3 million (Q1 2026), -$38.5 million (Q4 2025), and -$36.6 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.70 Bn | 78.71 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.27 Bn | 60.09 Bn | 1.37 Bn | - |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.80 Bn | 28.49 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 28.14 Bn | 9.75 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.26 Bn | 26.42 Bn | - | 9.79 Bn |
| 10 | Atara Biotherapeutics | 144.47 Mn | 127.92 Mn | 439,000.00 | -37.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -37.00 Mn |
| Mar 31, 2026 | -37.31 Mn |
| Dec 31, 2025 | -38.50 Mn |
| Sep 30, 2025 | -36.63 Mn |
| Jun 30, 2025 | -35.04 Mn |
| Mar 31, 2025 | -55.07 Mn |
| Dec 31, 2024 | -97.28 Mn |
| Sep 30, 2024 | -90.54 Mn |
| Jun 30, 2024 | -110.87 Mn |
| Mar 31, 2024 | -98.31 Mn |
| Dec 31, 2023 | 99.23 Mn |
| Sep 30, 2023 | -50.84 Mn |
| Jun 30, 2023 | 7.45 Mn |
| Mar 31, 2023 | 64.96 Mn |
| Dec 31, 2022 | 126.64 Mn |
| Sep 30, 2022 | 187.11 Mn |
| Jun 30, 2022 | 257.48 Mn |
| Mar 31, 2022 | 224.32 Mn |
| Dec 31, 2021 | 279.61 Mn |
| Sep 30, 2021 | 310.14 Mn |